Immunogenicity Risk Assessment of mRNA/LNP Therapies

Time: 10:00 am
day: Day One


  • Outlining the importance of the immunogenicity risk assessment for the development of safe mRNA/LNP therapies
  • Summarizing regulatory requirements and providing practical guidance on immunogenicity risk identification and evaluation
  • Emphasizing the impact of immunogenicity risk assessment on the bioanalytical monitoring strategy for all mRNA/LNP components during development